Paula Green Sells 918 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 918 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the sale, the senior vice president now owns 130,912 shares of the company's stock, valued at $5,355,609.92. The trade was a 0.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Paula Green also recently made the following trade(s):

• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $7,294.40.
• On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total transaction of $12,661.80.

Twist Bioscience Stock Up 1.7 %

TWST stock traded up $0.65 during mid-day trading on Friday, hitting $39.77. 396,260 shares of the company were exchanged, compared to its average volume of 992,561. The company has a market capitalization of $2.37 billion, a PE ratio of -11.77 and a beta of 2.15. The firm has a fifty day simple moving average of $45.91 and a 200 day simple moving average of $45.31. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same quarter last year, the business posted ($0.75) EPS. Twist Bioscience's quarterly revenue was up 24.1% compared to the same quarter last year. On average, research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the topic of a number of recent research reports. Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. TD Cowen reissued a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Wolfe Research started coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average target price of $54.40.

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC bought a new position in shares of Twist Bioscience in the 4th quarter worth about $56,984,000. Thrivent Financial for Lutherans bought a new position in Twist Bioscience in the third quarter worth about $43,992,000. Marshall Wace LLP boosted its stake in Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after acquiring an additional 840,828 shares during the period. State Street Corp grew its holdings in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock valued at $36,042,000 after purchasing an additional 521,272 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.